Loading
A phase 3 trial of cemiplimab in lung cancer, run by ETOP IBCSG Partners Foundation, now recruiting.
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy is a phase 3, randomised interventional study registered as NCT06931717 by ETOP IBCSG Partners Foundation, with a registry enrolment figure of 390 participants, started 2026-01-12 and due to reach its primary completion in 2029-03. Interventions recorded: Cemiplimab. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Disease-free survival (DFS). Lung eligibility wording from the registry: "* Pathological stage II-IIIA (UICC/ AJCC staging 9th edition) NSCLC Brain imaging should have been performed to complete staging, either preoperatively or postoperatively". Sites: Austria, Estonia, France, Germany, Ireland, Italy, Singapore, Spain, Switzerland. No results are recorded here; the registry entry is the source.
Shares Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Regeneron, Cemiplimab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Regeneron, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Regeneron, Cemiplimab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.